

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb60511</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>An in silico Design, Expression and Purification of a Chimeric Protein as an Immunogen Candidate Consisting of IpaD, StxB, and TolC Proteins from Shigella spp. </article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Fathi</surname><given-names>Javad</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Nazarian</surname><given-names>Shahram</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Kordbacheh</surname><given-names>Emad</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Hadi</surname><given-names>Nahal</given-names></name></contrib></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>14</volume>
      <issue>3</issue>
      <fpage>247</fpage>
      <lpage>258</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>7</month>
          <year>2022</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>7</month>
          <year>2022</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Background:&lt;/span&gt;&lt;em&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; Shigella&lt;/span&gt;&lt;/em&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; spp. is the cause of dysentery and is widespread worldwide. On the other hand, antibiotic resistance is increasing in this bacterium.&lt;/span&gt; &lt;span style=&quot;font-size:10.0pt&quot;&gt;Bioinformatics is a new approach to vaccine and drug design involving the selection of appropriate antigens.&lt;/span&gt; &lt;span style=&quot;font-size:10.0pt&quot;&gt;This study aimed to design a chimeric protein consisting of IpaD, StxB, and TolC proteins from &lt;em&gt;Shigella&lt;/em&gt; through a bioinformatics approach as an immunogen candidate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Methods:&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; The sequences of &lt;em&gt;ipaD&lt;/em&gt;, &lt;em&gt;stxB,&lt;/em&gt; and &lt;em&gt;tolC&lt;/em&gt; genes were obtained. Additionally, the immunogenic regions of the associated protein, physicochemical characteristics, protein structures, B and T cells epitopes, and molecular docking were determined using &lt;em&gt;in silico &lt;/em&gt;servers. Besides,&lt;/span&gt; &lt;span style=&quot;font-size:10.0pt&quot;&gt;the chimeric gene was synthesized following sequence optimization by utilizing the codon usage of &lt;em&gt;Escherichia coli &lt;/em&gt;(&lt;em&gt;E. coli)&lt;/em&gt;. The expression of the recombinant protein was confirmed &lt;em&gt;via&lt;/em&gt; SDS-PAGE and Western blot technique. &lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Results:&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; The residues 41-160 of IpaD, 21-89 of StxB, and 40-335 of TolC were selected. According to half-life, instability, and buried indices, IpaD-StxB-TolC was selected as the best arrangement. The Ramachandran plot showed that 97.077% of the amino acids were in the favored area. Linear and conformational epitopes were also present throughout the chimeric protein sequence. Moreover,&lt;/span&gt; &lt;span style=&quot;font-size:10.0pt&quot;&gt;the C-ImmSim server indicated that IgG and IgM titers could reach desirable values by the third injection&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;. &lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt;Furthermore, the stability of the mRNA-optimized gene was enhanced, increasing the Codon Adaptive Index (CAI) to 0.9. Finally, the chimeric gene was transferred to &lt;em&gt;E. coli&lt;/em&gt; BL21, and the expression of the 60.6 &lt;em&gt;kDa&lt;/em&gt; recombinant protein was confirmed.&amp;nbsp; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style=&quot;text-align:justify&quot;&gt;&lt;span style=&quot;font-size:11pt&quot;&gt;&lt;span style=&quot;font-size:9.5pt&quot;&gt;Conclusion:&lt;/span&gt;&lt;span style=&quot;font-size:10.0pt&quot;&gt; The results indicated that the recombinant protein could act as a proper immunogen candidate against &lt;em&gt;Shigella&lt;/em&gt; spp.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
